AKT-independent PI3-K signaling in cancer - Emerging role for SGK3

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 281-292

  Bruhn, Maressa A ^a,e   Pearson, Richard B ^a,b,c   Hannan, Ross D ^a,b,c,d   Sheppard, Karen E ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

AKT; Cancer; MTOR; PI3 kinase; SGK3

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REGULATOR PROTEIN; SERUM AND GLUCOCORTICOID INDUCIBLE PROTEIN KINASE 3; UNCLASSIFIED DRUG;

CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE K RAS; PIK3CA GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84883231503     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S35178     Document Type: Review

References (125)

1. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog. 2012;17(1):69-95.
2. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17-S27.
3. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol. 2012;13(3): 195-203.
4. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
5. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 29 2007;129(7):1261-1274.
6. Shaw RJ, Bardeesy N, Manning BD, etal. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6(1):91-99.
7. Wandzioch E, Edling CE, Palmer RH, Carlsson L, Hallberg B. Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines. Blood. 2004;104(1):51-57.
8. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005; 121(2):179-193.
9. Solomon B, Pearson RB. Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol. 2009;4(7): 787-791.
10. Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol. 2003;7(2):205-228.
11. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
12. Mills GB, Lu Y, Fang X, etal. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001; 28(5 Suppl 16):125-141.
13. Gagliardi PA, di Blasio L, Orso F, etal. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia. 2012;14(8):719-731.
14. Kinross KM, Montgomery KG, Kleinschmidt M, etal. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest. 2012;122(2):553-557.
15. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, etal. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68(15):6084-6091.
16. Chou MM, Hou W, Johnson J, etal. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol. 1998;8(19):1069-1077.
17. Mizuno H, Nishida E. The ERK MAP kinase pathway mediates induction of SGK (serum-and glucocorticoid-inducible kinase) by growth factors. Genes Cells. 2001;6(3):261-268.
18. Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth Factors. 2010;28(6):394-408.
19. Tessier M, Woodgett JR. Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem. 2006;98(6): 1391-1407.
20. Liu M, Chen LL, Chan TH, etal. Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. Hepatology. 2012;55(6):1754-1765.
21. Vasudevan KM, Barbie DA, Davies MA, etal. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16(1):21-32.
22. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-341.
23. Fruman DA. Regulatory subunits of class IA PI3K. Curr Top Microbiol Immunol. 2010;346:225-244.
24. Vogt PK, Hart JR, Gymnopoulos M, etal. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol. 2010;347:79-104.
25. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009;21(2):199-208.
26. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20(1):87-90.
27. Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321(1): 20-28.
28. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(1):65-80.
29. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657.
30. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 2010;1(7):530-543.
31. Hu P, Margolis B, Skolnik EY, Lammers R, Ullrich A, Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol. 1992;12(3):981-990.
32. McGlade CJ, Ellis C, Reedijk M, etal. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol. 1992;12(3):991-997.
33. Zhu G, Decker SJ, Saltiel AR. Direct analysis of the binding of Src-homology 2 domains of phospholipase C to the activated epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1992;89(20): 9559-9563.
34. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004;3(10):1221-1224.
35. Samuels Y, Wang Z, Bardelli A, etal. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
36. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol. 2010;21(4):683-691.
37. Zhao JJ, Cheng H, Jia S, etal. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A. 2006;103(44):16296-16300.
38. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23(6):1518-1525.
39. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41.
40. Philp AJ, Campbell IG, Leet C, etal. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61(20):7426-7429.
41. Isakoff SJ, Engelman JA, Irie HY, etal. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65(23):10992-11000.
42. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, etal. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561-573.
43. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006;18(1):77-82.
44. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921-929.
45. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102(51):18443-18448.
46. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007; 104(13):5569-5574.
47. Vogt PK, Gymnopoulos M, Hart JR. PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev. 2009;19(1):12-17.
48. Shekar SC, Wu H, Fu Z, etal. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem. 2005;280(30):27850-27855.
49. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011;2(3):261-274.
50. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008;410(1):1-17.
51. Yan Y, Backer JM. Regulation of class III (Vps34) PI3Ks. Biochem Soc Trans. 2007;35(Pt 2):239-241.
52. Yan Y, Flinn RJ, Wu H, Schnur RS, Backer JM. hVps15, but not Ca2+/CaM, is required for the activity and regulation of hVps34in mammalian cells. Biochem J. 2009;417(3):747-755.
53. Thoresen SB, Pedersen NM, Liestol K, Stenmark H. A phosphati-dylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res. 2010;316(20):3368-3378.
54. Nobukuni T, Joaquin M, Roccio M, etal. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A. 2005;102(40):14238-14243.
55. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem. 2005; 280(38):33076-33082.
56. Gulati P, Gaspers LD, Dann SG, etal. Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab. 2008;7(5): 456-465.
57. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-293.
58. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10(8): 935-945.
59. Sancak Y, Peterson TR, Shaul YD, etal. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008; 320(5882):1496-1501.
60. Findlay GM, Yan L, Procter J, Mieulet V, Lamb RF. A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J. 2007;403(1):13-20.
61. Kim S, Kim SF, Maag D, etal. Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase. Cell Metab. 2011;13(2): 215-221.
62. Hannan KM, Brandenburger Y, Jenkins A, etal. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol. 2003;23(23): 8862-8877.
63. Yang X, Yang C, Farberman A, etal. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth. J Anim Sci. 2008;86(Suppl 14):E36-E50.
64. Wang X, Proud CG. The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 2006;21:362-369.
65. James MJ, Zomerdijk JC. Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients. J Biol Chem. 2004;279(10):8911-8918.
66. Corradetti MN, Guan KL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene. 2006;25(48): 6347-6360.
67. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4(9):a011189.
68. Sancak Y, Thoreen CC, Peterson TR, etal. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007; 25(6):903-915.
69. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9(3):316-323.
70. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2(4):339-345.
71. Brunet A, Bonni A, Zigmond MJ, etal. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96(6):857-868.
72. Datta SR, Dudek H, Tao X, etal. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2): 231-241.
73. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598-11603.
74. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401(6748):86-90.
75. Chan JC, Hannan KM, Riddell K, etal. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal. 2011;4(188):ra56.
76. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987;84(14): 5034-5037.
77. Bellacosa A, de Feo D, Godwin AK, etal. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995;64(4):280-285.
78. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004.
79. Carpten JD, Faber AL, Horn C, etal. A transforming mutation in the pleckstrin homology domain of AKT1in cancer. Nature. 2007;448(7152):439-444.
80. Yuan ZQ, Sun M, Feldman RI, etal. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19(19): 2324-2330.
81. Stahl JM, Sharma A, Cheung M, etal. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004; 64(19):7002-7010.
82. Cristiano BE, Chan JC, Hannan KM, etal. A specific role for AKT3in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res. 2006;66(24):11718-11725.
83. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
84. Wu R, Hendrix-Lucas N, Kuick R, etal. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11(4):321-333.
85. Zhang W, Haines BB, Efferson C, etal. Evidence of mTOR Activation by an AKT-independent mechanism provides support for the combined treatment of PTEN-deficient prostate tumors with mTOR and AKT inhibitors. Transl Oncol. 2012;5(6):422-429.
86. Xu J, Wan M, He Q, etal. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat. 2012;134(2): 531-541.
87. Creighton CJ. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. Oncogene. 2007;26(32):4648-4655.
88. Sommer EM, Dry H, Cross D, Guichard S, Davies BR, Alessi DR. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. Biochem J. 2013;452(3):499-508.
89. De Marco C, Rinaldo N, Bruni P, etal. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS One. 2013;8(2):e55362.
90. Liu D, Yang X, Songyang Z. Identification of CISK, a new member of the SGK kinase family that promotes IL-3-dependent survival. Curr Biol. 2000;10(19):1233-1236.
91. Dai F, Yu L, He H, etal. Cloning and mapping of a novel human serum/glucocorticoid regulated kinase-like gene, SGKL, to chromosome 8q12.3-q13.1. Genomics. 1999;62(1):95-97.
92. Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol. 2011;25(1):72-82.
93. Ellson CD, Andrews S, Stephens LR, Hawkins PT. The PX domain: a new phosphoinositide-binding module. J Cell Sci. 2002;115(Pt 6): 1099-1105.
94. Virbasius JV, Song X, Pomerleau DP, Zhan Y, Zhou GW, Czech MP. Activation of the Akt-related cytokine-independent survival kinase requires interaction of its phox domain with endosomal phosphatidylinositol 3-phosphate. Proc Natl Acad Sci U S A. 2001; 98(23):12908-12913.
95. Xu J, Liu D, Gill G, Songyang Z. Regulation of cytokine-independent survival kinase (CISK) by the Phox homology domain and phosphoinositides. J Cell Biol. 2001;154(4):699-705.
96. Kobayashi T, Deak M, Morrice N, Cohen P. Characterization of the structure and regulation of two novel isoforms of serum-and glucocorticoid-induced protein kinase. Biochem J. 1999;344 Pt 1: 189-197.
97. Firestone GL, Giampaolo JR, O'Keeffe BA. Stimulus-dependent regulation of serum and glucocorticoid inducible protein kinase (SGK) transcription, subcellular localization and enzymatic activity. Cell Physiol Biochem. 2003;13(1):1-12.
98. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008;416(3):375-385.
99. Lu M, Wang J, Jones KT, etal. mTOR complex-2 activates ENaC by phosphorylating SGK1. J Am Soc Nephrol. 2010;21(5):811-818.
100. Lyo D, Xu L, Foster DA. Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway. Biochem Biophys Res Commun. 2010;396(2):562-565.
101. Park J, Leong ML, Buse P, Maiyar AC, Firestone GL, Hemmings BA. Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J. 1999;18(11): 3024-3033.
102. Tessier M, Woodgett JR. Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3. J Biol Chem. 2006;281(33):23978-23989.
103. Kobayashi T, Cohen P. Activation of serum-and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J. 1999;339(Pt 2):319-328.
104. Sanchez Canedo C, Demeulder B, Ginion A, etal. Activation of the cardiac mTOR/p70(S6K) pathway by leucine requires PDK1 and correlates with PRAS40 phosphorylation. Am J Physiol Endocrinol Metab. 2010;298(4):E761-E769.
105. Slagsvold T, Marchese A, Brech A, Stenmark H. CISK attenuates degradation of the chemokine receptor CXCR4 via the ubiquitin ligase AIP4. EMBO J. 2006;25(16):3738-3749.
106. Frodin M, Antal TL, Dummler BA, etal. A phosphoserine/threonine-binding pocket in AGC kinases and PDK1mediates activation by hydrophobic motif phosphorylation. EMBO J. 2002;21(20): 5396-5407.
107. Collins BJ, Deak M, Arthur JS, Armit LJ, Alessi DR. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 2003;22(16):4202-4211.
108. Biondi RM, Kieloch A, Currie RA, Deak M, Alessi DR. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 2001;20(16):4380-4390.
109. Xu J, Liao L, Qin J, Liu D, Songyang Z. Identification of flightless-I as a substrate of the cytokine-independent survival kinase CISK. J Biol Chem. 2009;284(21):14377-14385.
110. McCormick JA, Feng Y, Dawson K, etal. Targeted disruption of the protein kinase SGK3/CISK impairs postnatal hair follicle development. Mol Biol Cell. 2004;15(9):4278-4288.
111. Alonso L, Okada H, Pasolli HA, etal. Sgk3 links growth factor signaling to maintenance of progenitor cells in the hair follicle. J Cell Biol. 2005;170(4):559-570.
112. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem. 1999;274(16):10963-10968.
113. Grahammer F, Artunc F, Sandulache D, etal. Renal function of gene-targeted mice lacking both SGK1 and SGK3. Am J Physiol Regul Integr Comp Physiol. 2006;290(4):R945-R950.
114. Mauro TM, McCormick JA, Wang J, etal. Akt2 and SGK3 are both determinants of postnatal hair follicle development. FASEB J. 2009;23(9):3193-3202.
115. Yao LJ, McCormick JA, Wang J, etal. Novel role for SGK3in glucose homeostasis revealed in SGK3/Akt2 double-null mice. Mol Endocrinol. 2011;25(12):2106-2118.
116. Cho H, Mu J, Kim JK, etal. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728-1731.
117. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol. 2001;21(3):952-965.
118. Ho KK, Myatt SS, Lam EW. Many forks in the path: cycling with FoxO. Oncogene. 2008;27(16):2300-2311.
119. Dai F, Yu L, He H, etal. Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction. Biochem Biophys Res Commun. 2002;293(4):1191-1196.
120. Hannan KM, Sanij E, Hein N, Hannan RD, Pearson RB. Signaling to the ribosome in cancer-it is more than just mTORC1. IUBMB Life. 2011;63(2):79-85.
121. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606-619.
122. Failor KL, Desyatnikov Y, Finger LA, Firestone GL. Glucocorticoid-induced degradation of glycogen synthase kinase-3 protein is triggered by serum-and glucocorticoid-induced protein kinase and Akt signaling and controls beta-catenin dynamics and tight junction formation in mammary epithelial tumor cells. Mol Endocrinol. 2007;21(10): 2403-2415.
123. Gassmann P, Haier J, Schluter K, etal. CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia. 2009;11(7):651-661.
124. Muller A, Homey B, Soto H, etal. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50-56.
125. Lang F, Voelkl J. Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opin Investig Drugs. 2013;22(6): 701-714.